The Eisai Co., which now owns the anti-nausea drug Aloxi, has won federal approval for an additional Aloxi use and is pursuing approval for more, citing that as justification for a six-month extension of the Aloxi patent beyond April 2015.
about the writer
The rise of target-date funds, though criticized as a one-size-fits-all approach, has relieved workers of the task of creating and managing portfolios. The only decision is guesstimating the year of retirement.
